Kallman syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 20: Line 20:
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:Syndromes]]
[[Category:Syndromes]]
[[Category:Needs content]]

Latest revision as of 16:36, 19 September 2012

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Kallman syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Kallman Syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Social Impact

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kallman syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kallman syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kallman syndrome medical therapy

CDC on Kallman syndrome medical therapy

Kallman syndrome medical therapy in the news

Blogs on Kallman syndrome medical therapy

Directions to Hospitals Treating Kallman syndrome

Risk calculators and risk factors for Kallman syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Treatment is directed at restoring the deficient hormones -- known as hormone therapy (HT). Males are administered human chorionic gonadotropin (hCG) or testosterone. Females are treated with oestrogen and progestins.

To induce fertility in males or females, GnRH (aka LHRH) is administered by an infusion pump, or hCG/hMG/FSH/LH combinations are administered through regular injections. Fertility is only maintained whilst actually being treated with these hormones. Once fertility treatment stops it is necessary to revert to the normal HRT of testosterone for men and oestrogen + progestins for women.

The main health risk, for both men and women, of untreated Kallmann Syndrome is osteoporosis. Therefore, regular bone density scans (every 2 years or so) are advisable, even if being treated with HRT. Additional medication specifically for osteoporosis is necessary in some cases.

References

Template:WH Template:WS